Intended Use
The Anti-Phospholipid Screen ELISA Assay Kit is used for the separate quantitative determination of IgG and / or IgM antibodies to phospholipides (cardiolipin, phosphatidyl-serine, -inositol, -ethanolamine, phosphatidic acid and β2 glycoprotein I) in human serum for the diagnosis of antiphospholipid antibody syndrome (APAS).
Contents of Kit
A. Microtiter plate: 12 breakable strips per 8 wells coated with cardiolipin, phosphatidyl-serine, -inositol, -ethanolamine, phosphatidic acid (bovine) and β2 glycoprotein I (human), on each well, 1, vacuum sealed with desiccant
B. Concentrated wash buffer (10x): sufficient for 1000 ml solution. 100 ml, concentrate, capped white
C. Sample diluent: 100 ml, concentrate, capped black
D. Conjugate: containing anti-human-IgG- (sheep) coupled with horseradish peroxidase, 15 ml, ready for use, capped red
E. Conjugate: containing anti-human-IgM- (sheep) coupled with HRP, 15 ml, ready for use, capped green
F. Substrate: 3,3',5,5'-tetramethylbenzidine in citrate buffer containing hydrogen peroxide, 15 ml, ready for use, capped blue
G. Stop solution: 0.25 sulfuric acid (0.25M), 15 ml, ready for use, capped yellow
0-4. Calibrators: diluted sera, conc.: 1, 10, 30, 100, 300 U/ml, 1 ml each, ready for use, capped white
P. Positive control: diluted serum, conc.: see leaflet enclosed, 1 ml, ready for use, capped red
N. Negative control: diluted serum, conc.: see leaflet enclosed, 1 ml, ready for use, capped green
Storage
1. The expiry date of each component is reported on its respective label that of the complete kit on the box labels.
2. Upon receipt, all components of the AntiPhospholipid screen have to be kept at 2 - 8 °C, preferably in the original kit box.
3. After opening all kit components are stable for at least 2 months, provided proper storage.
General Description
APAS is an autoimmune disorder comprising such clinical symptoms like arterial or venous thrombosis, thrombocytopenia and recurrent fetal loss. Primary APAS as well as systemic lupus erythematosus (SLE) are characterized by the appearance of autoantibodies to negatively charged phospholipids. Although significance and pathological relevance of phospholipid antibodies are not completely revealed yet, the detection of such autoantibodies is widely established and plays an important role in the diagnostics of systemic autoimmune diseases.
Unlike phospholipid antibodies which appear in some infectious disease patients autoimmune patients exhibit phospholipid antibodies that seem to recognize phospholipids in association with plasma protein cofactors such as β2 glycoprotein-I (β2 GP-I) (apolipoprotein H). β2 GP-I, a serum protein with a molecular weight of 50 kDa, affects platelet aggregation and coagulation.
The positively charged fifth domain of β2 GP-I interacts with negatively charged phospholipids such as Cardiolipin. This interaction results in conformational changes of the protein and the creation of new epitopes apparently recognized by autoimmune phospholipid autoantibodies.
COA
Publication 
Loading ......
